Response-based Treatment of High-risk Neuroblastoma


The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2020

Detailed Description

Although the outcome of high-risk neuroblastoma improved after the introduction of high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT), the outcome still needs to be unsatisfactory.

In the investigator's previous study, good responders who had greater reduction of tumor volume after induction chemotherapy showed lower relapse-free survival compared to poor responders.Simultaneously, the reduction in tumor volume also was greater in patients who died of treatment related mortality than patients who had relapsed tumors. These findings suggest that tailoring treatment intensity according to the early tumor response to induction chemotherapy may improve patient outcomes. So, in this study investigators tailored the treatment intensity of high dose chemotherapy according to the treatment response to induction chemotherapy.


  • Drug: Cisplatin
  • Drug: Doxorubicin
  • Drug: Etoposide
  • Drug: Cyclophosphamide
  • Drug: Ifosfamide
  • Drug: Carboplatin
  • Procedure: Tandem HDCT/auto-SCT
  • Radiation: Radiotherapy
  • Drug: Interleukin-2
  • Drug: Isotretinoin
  • Radiation: MIBG

Arms, Groups and Cohorts

  • Experimental: High risk neuroblastoma
    • Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen Upfront surgery or surgery after 6 cycles of chemotherapy Peripheral stem cell mobilization after 7 cycles of chemotherapy Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT) Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT Radiotherapy after tandem HDCT Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin

Clinical Trial Outcome Measures

Primary Measures

  • Rate of event free survival
    • Time Frame: Up to 3 years

Secondary Measures

  • Rate of late adverse effects
    • Time Frame: Up to 3 years

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with newly diagnosed high risk neuroblastoma
  • Patients with informed consent

Exclusion Criteria

  • Patients with progressive disease or relapse
  • Patients who underwent high dose chemotherapy before
  • Patients with organ dysfunction as follows (creatinine elevation > 3 x upper limit of normal, Total bilirubin > 3 x upper limit of normal, aspartate transaminase/alanine transaminase > 5 x upper limit of normal), ejection fraction <40%
  • Pregnant or nursing women

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Samsung Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ki Woong Sung, MD, PhD, Principal Investigator, Samsung Medical Center
  • Overall Contact(s)
    • Ki Woong Sung, MD, PhD, 82-2-3410-3529,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.